Patent classifications
A23V2250/1586
Nutritional formulations and kits for bariatric individuals
The present technology relates to a nutritional formulation for administration to bariatric individuals. The nutritional formulation includes a multi-nutrients dosage unit; and a minerals dosage unit.
FEED SUPPLEMENTS
Disclosed herein are embodiments of a combination and/or composition comprising a growth factor and one or more of silica, mineral clay, glucan, mannans, endoglucanohydrolase, yucca, quillaja, metal chelate, chromium compound, probiotic, polyphenol, direct fed microbial, copper species, vitamin, allicin, alliin, alliinase, yeast, growth promotant, preservative, antimicrobial, or vaccine. The growth factor may be an active growth factor such as an active insulin-like growth factor. Also disclosed are methods of administering the combination and/or composition to an animal. The combination and/or composition may provide a beneficial effect to the animal upon administration, such as, but not limited to, improved immune function, metabolism, milk production, growth, feed conversion, fertilization, reproduction, oocyte quality in a ruminant undergoing superovulation, embryo viability, muscle growth, muscle percentage, heart muscle development, egg product and/or quality, sperm production and/or quality, meat quality, or a combination thereof.
FEED SUPPLEMENTS
Disclosed herein are embodiments of a combination and/or composition comprising a growth factor and one or more of silica, mineral clay, glucan, mannans, endoglucanohydrolase, yucca, quillaja, metal chelate, chromium compound, probiotic, polyphenol, direct fed microbial, copper species, vitamin, allicin, alliin, alliinase, yeast, growth promotant, preservative, antimicrobial, or vaccine. The growth factor may be an active growth factor such as an active insulin-like growth factor. Also disclosed are methods of administering the combination and/or composition to an animal. The combination and/or composition may provide a beneficial effect to the animal upon administration, such as, but not limited to, improved immune function, metabolism, milk production, growth, feed conversion, fertilization, reproduction, oocyte quality in a ruminant undergoing superovulation, embryo viability, muscle growth, muscle percentage, heart muscle development, egg product and/or quality, sperm production and/or quality, meat quality, or a combination thereof.
COMPOSITION AND METHOD FOR RAPIDLY INDUCING AN ENDOGENOUS KETOSIS
A composition and method for rapidly inducing a state of endogenous ketosis, the composition including: about 26.66-28.57 percent by mass of alpha lipoic acid; about 0.01-0.02 percent by mass of chromium picolinate; about 47.61-49.99 percent by mass of L-arginine; and, about 23.33-23.81 percent by mass of calcium carbonate. The method includes restricting carbohydrate consumption to a maximum dosage of about 20 grams prior to consumption of the composition and wherein consumption of the composition is on an empty stomach. About thirty minutes after consumption of the composition the user performs moderate intensity exercise. About three hours after consuming a first dose the user tests for a presence of ketones in urine utilizing at least one sodium nitroprusside urine ketone reagent strip.
COMPOSITION AND METHOD FOR RAPIDLY INDUCING AN ENDOGENOUS KETOSIS
A composition and method for rapidly inducing a state of endogenous ketosis, the composition including: about 26.66-28.57 percent by mass of alpha lipoic acid; about 0.01-0.02 percent by mass of chromium picolinate; about 47.61-49.99 percent by mass of L-arginine; and, about 23.33-23.81 percent by mass of calcium carbonate. The method includes restricting carbohydrate consumption to a maximum dosage of about 20 grams prior to consumption of the composition and wherein consumption of the composition is on an empty stomach. About thirty minutes after consumption of the composition the user performs moderate intensity exercise. About three hours after consuming a first dose the user tests for a presence of ketones in urine utilizing at least one sodium nitroprusside urine ketone reagent strip.
Compositions of coenzyme Q10 and methods of use
In an embodiment, a nutritional supplement including, about 0.5 mg to about 4 mg of folate, about 6.25 mg to about 50 mg of vitamin B-6, about 250 mcg to about 2000 mcg of vitamin B-12, about 75 mg to about 600 mg of coenzyme Q10 (CoQ10), about 1250 IU to about 10,000 IU of vitamin D.sub.3, about 25 mg to about 200 mg of magnesium, about 25 mg to 200 mg of N-acetyl-L-cysteine, about 5 mg to about 40 mg pyrroloquinoline quinone disodium (PQQ), about 25 mg to about 200 mg of curcumin extract, about 25 mg to about 200 mg of resveratrol, about 25 mg to about 200 mg berberine, about 12.5 mcg to about 100 mcg of chromium, and about 12.5 mcg to about 100 mcg of selenium. In an additional embodiment, the aforementioned nutritional supplement in a nutritional kit that further includes an omega-3 supplement.
Compositions of coenzyme Q10 and methods of use
In an embodiment, a nutritional supplement including, about 0.5 mg to about 4 mg of folate, about 6.25 mg to about 50 mg of vitamin B-6, about 250 mcg to about 2000 mcg of vitamin B-12, about 75 mg to about 600 mg of coenzyme Q10 (CoQ10), about 1250 IU to about 10,000 IU of vitamin D.sub.3, about 25 mg to about 200 mg of magnesium, about 25 mg to 200 mg of N-acetyl-L-cysteine, about 5 mg to about 40 mg pyrroloquinoline quinone disodium (PQQ), about 25 mg to about 200 mg of curcumin extract, about 25 mg to about 200 mg of resveratrol, about 25 mg to about 200 mg berberine, about 12.5 mcg to about 100 mcg of chromium, and about 12.5 mcg to about 100 mcg of selenium. In an additional embodiment, the aforementioned nutritional supplement in a nutritional kit that further includes an omega-3 supplement.
PEPTIDE COMPOSITIONS FOR SLOWING DEGRADATION OF VITAMIN MINERAL SUPPLEMENTS, FOODS, PHARMACEUTICAL AND COSMETICS
Compositions of foods, vitamin and mineral supplements, topical or oral drugs, and cosmetic products containing a small peptide or peptides for slowing degradation, for example by transition metals. The peptides are di, tri, terra-, and/or penta-peptides containing two or more aspartic acid residues. The degradation of several of the vitamin and other constituents vitamin-mineral supplements can be considerably slowed by composition incorporating such peptides, particularly if soluble (and thus bioavailable) forms of copper and/or iron are also present. The peptides can be hydrolyzed by the normal digestive process thus releasing bound metals. Multiple aspartate peptide(s) compositions with foods, topical or oral drugs, cosmetic, and hair care products can replace synthetic chelating preservative agents. Methods are also described to effectively slow degradation and preserve the above products using multiple aspartate peptides.
PEPTIDE COMPOSITIONS FOR SLOWING DEGRADATION OF VITAMIN MINERAL SUPPLEMENTS, FOODS, PHARMACEUTICAL AND COSMETICS
Compositions of foods, vitamin and mineral supplements, topical or oral drugs, and cosmetic products containing a small peptide or peptides for slowing degradation, for example by transition metals. The peptides are di, tri, terra-, and/or penta-peptides containing two or more aspartic acid residues. The degradation of several of the vitamin and other constituents vitamin-mineral supplements can be considerably slowed by composition incorporating such peptides, particularly if soluble (and thus bioavailable) forms of copper and/or iron are also present. The peptides can be hydrolyzed by the normal digestive process thus releasing bound metals. Multiple aspartate peptide(s) compositions with foods, topical or oral drugs, cosmetic, and hair care products can replace synthetic chelating preservative agents. Methods are also described to effectively slow degradation and preserve the above products using multiple aspartate peptides.
Prebiotic compositions and uses thereof
The present invention relates to compositions for weight management comprising: a) a microbiome modifying component; b) a satiety modifying component; and c) a metabolic modifying component. The composition may also be used for the treatment of obesity, elevated cholesterol, diabetes, hypertension or heart disease.